Literature DB >> 22691890

Role of the IGF axis in prostate cancer.

K M Biernacka1, C M Perks, J M P Holly.   

Abstract

The major issue currently being faced in the management of prostate cancer is the inability to distinguish between indolent prostate tumors that will not present clinically from more aggressive and metastatic prostate cancers that will impact on men's lives. Only a small proportion of prostate cancers can be accounted for by unmistakable hereditary cancer syndromes and the predominant contribution to the progression of most sporadic cancers is thought to be environmental, with nutrition having the greatest influence. Population studies have clearly implicated metabolic factors as contributors to disease progression and poor response to therapy. It is well established that the IGF system is key in regulating growth and metabolism and mediates the effects of nutrition on these processes. It consists of two ligands (IGF-I and IGF-II), two receptors [type 1 IGF-IR and IGF-II/mannose 6-phosphate receptor], and six high affinity IGF-binding proteins (IGFBP-1 to -6). This review provides evidence from in vitro, in vivo, clinical and epidemiology studies that indicates an important role for the IGF axis in the development of prostate cancer and the likely role that it plays in mediating the effects of nutrition on disease progression. We suggest that the IGF axis is central to understanding how lifestyle impacts on prostate cancer and we highlight this by describing numerous strategies being developed to target this axis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691890

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  6 in total

1.  Sleep and insulin-like growth factors in the Cardiovascular Health Study.

Authors:  Neomi Shah; Tom Rice; Daniel Tracy; Thomas Rohan; Petra Bůžková; Anne Newman; Robert C Kaplan
Journal:  J Clin Sleep Med       Date:  2013-12-15       Impact factor: 4.062

2.  Insulin Receptor Isoform Variations in Prostate Cancer Cells.

Authors:  Claire M Perks; H A Zielinska; Jing Wang; Caroline Jarrett; A Frankow; Michael R Ladomery; Amit Bahl; Anthony Rhodes; Jon Oxley; Jeff M P Holly
Journal:  Front Endocrinol (Lausanne)       Date:  2016-09-28       Impact factor: 5.555

Review 3.  Profiling Prostate Cancer Therapeutic Resistance.

Authors:  Cameron A Wade; Natasha Kyprianou
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

Review 4.  Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.

Authors:  Fabrizio Fontana; Patrizia Limonta
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

Review 5.  Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-β and IGF signaling.

Authors:  Chung Lee; Zhenyu Jia; Farah Rahmatpanah; Qiang Zhang; Xiaolin Zi; Michael McClelland; Dan Mercola
Journal:  Biomed Res Int       Date:  2014-06-25       Impact factor: 3.411

6.  Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.

Authors:  Zheng Cao; Shahriar Koochekpour; Stephen E Strup; Natasha Kyprianou
Journal:  Oncotarget       Date:  2017-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.